A lthough neuronal apoptosis is a normal event during development, many neurodegenerative diseases are thought to involve abnormal cell death that leads to damage of the nervous system (1) . Current therapies to treat, e.g., Alzheimer's disease (AD), rely on intensifying the actions of remaining cells but do not halt disease progression or prevent cell loss (2) . Consequently, there has been great interest in the use of neurotrophic factors as therapeutic agents to inhibit cell loss associated with AD and other neurodegenerative diseases (1) .
Some of the most promising candidates in drug development for neurodegenerative diseases have been the insulin-like growth factors (IGFs), known for their pleiotrophic roles in promoting cellular survival, proliferation, and differentiation (3) . Importantly, the levels of circulating IGF-I are known to decrease during aging, and recently a possible link between low-serum IGF-I and accumulation of amyloid-␤ (A␤) in the brain has been reported (4) . IGF-I may be a key factor in regulating the clearance of A␤ from the brain through carrier-mediated transport (4) . Furthermore, IGF-I has been shown to protect against several neurodegenerative conditions both in vitro and in vivo, including A␤-induced cell death (5) .
IGF-binding proteins (IGFBPs) have been shown to have an essential role in the regulation of cell survival, not only through regulation of free bioactive IGFs, but also via several IGFindependent effects. In particular, IGFBP-3 has been shown to induce apoptosis and inhibit cell growth independently of IGFs (6) . IGFBP-3 rapidly translocates to the nucleus, where it specifically and functionally interacts with nuclear proteins, including the nuclear retinoid receptor, RXR␣ (6, 7) . In addition, IGFBP-3 is up-regulated by proapoptotic signal transduction pathways, including tumor necrosis factor ␣, transforming growth factor ␤, and the tumor suppressor p53 (8, 9) .
The functional roles of IGFBPs in the CNS are still being unraveled. The expression of IGFBPs is known to change in the CNS in response to various insults (10, 11) . Recently IGFBP-3 mRNA and protein expression was shown to be significantly up-regulated in AD brain tissue and in response to A␤ exposure in human brain pericytes in vitro (12) . This up-regulation of proapoptotic IGFBPs may contribute to neuronal degeneration and apoptosis and subsequently to neuronal loss and clinical symptoms in AD. Importantly, IGF-I-induced neuronal protection against A␤ in vitro is IGFBP-3-sensitive: IGFBP-3 abolishes IGF-I-induced survival (5) . In the current study, we demonstrate the interaction between IGFBP-3 and an AD-related survival peptide named humanin (HN). HN is a recently described AD-related survival peptide of major therapeutic potential (13, 14) . This survival-promoting peptide was cloned from a cDNA library extracted from surviving neurons of the occipital lobe of Alzheimer brain and was shown to potently and specifically inhibit neuronal death induced by exogenous A␤ and expression of familial AD mutant genes (14) . Recently, HN was shown to bind the proapoptotic Bcl-2 family member, Bax, and convey part of its antiapoptotic effects through inhibition of Bax activation (15) .
We describe herein the physical association between IGFBP-3 and HN in vitro and in vivo, identify the binding sites for these molecules, and demonstrate functional effects of HN-IGFBP-3 interaction on cell survival and apoptosis. I-IGFBP-3 and affinity-purified anti-human IGFBP-3 antibody were purchased from DSL (Webster, TX). Rabbit polyclonal anti-HN antibody was generated by Harlan Bioproducts for Science (Madison, WI). A␤ (1-43) peptide was from Peptide Institute (Osaka) (see Supporting Text, which is published as supporting information on the PNAS web site, www.pnas.org, for more information).
Materials

Methods
Yeast Two-Hybrid Screening and Yeast Mating Assays. Briefly, the yeast strain Saccharomyces cerevisiae HF7c was purchased from Clontech. The fusion gene IGFBP-3͞BD was constructed by splicing cDNA encoding the human IGFBP-3 gene into the plasmid pGBT9. A HeLa cDNA library with the activation domain of the GAL4 gene was purchased from Clontech and screened by cotransforming yeast with both plasmids (Clontech Matchmaker protocol handbook). Positive cotransformants were selected, and genes encoding IGFBP-3-binding proteins were isolated by plasmid recovery, amplified, sequenced by using a GAL4 activation domain sequencing primer, and compared with known sequences in GenBank by using the MACVECTOR software program (Oxford Molecular, Williamstown, MA) (see Supporting Text for more information).
Ligand Dot Blot. Western ligand blots were used to assess IGFBP-3 binding as described (6) .
Cross-Linking. Cross-linking was performed according to standard procedures. Disuccinimidylsuberate at 0.3 mg͞ml was used as a cross-linker. Samples were subjected to SDS͞PAGE and autoradiography.
Alanine Scanning. pAla-scanned HN plasmids (14) pHN or pL9R-HN (1 g of DNA) were transfected in triplicate to F11 cells (14) (7 ϫ 10 4 cells per well on six-well plates) with Lipofectamine plus. Cell lysates were precipitated with M2 antibody, and 1 or 10 nmol rhIGFBP-3 was eluted through the column according to the standard protocols.
Pull-Down. One nanomolar rhIGFBP3 (Upstate Biotechnology, Lake Placid, NY) was mixed with Ni-NTA agarose beads (Qiagen, Hilden, Germany) immobilizing (His) 6x -tagged HN peptides. After the beads were washed, immunoblotting with anti-IGFBP-3 specific antibody was performed according to the standard protocols.
Immunoprecipitation and Immunoblotting. For the coimmunoprecipitation of HN and IGFBP-3 in vitro, A172 cells were treated with 10 M HN overnight in serum-free conditions. Whole-cell extracts from HN-treated cells were immunoprecipitated according to the standard protocols. For the coimmunoprecipitation of HN and IGFBP-3 in vivo, testes of 3-wk-old mice were homogenized and immunoprecipitated according to the standard protocols.
Cell Culture. A172 glioblastoma and SH-SY5Y neuroblastoma cells (American Type Culture Collection) were maintained and subcultured according to standard procedures. F11 cells and mouse cortical neurons were cultured as described (14) .
Caspase Assays. Caspase assay was done by using Apo-ONE homogenous caspase-3͞-7 assay (Promega) and performed according to manufacturer's instructions.
Terminal Deoxynucleotidyltransferase-Mediated dUTP Nick End Labeling (TUNEL) Staining. TUNEL staining was performed by using the DeadEnd Colorimetric TUNEL system (Promega) according to the manufacturer's instructions.
WST-8 and Calcein Assays. Primary cortical neurons were treated with or without 25 M A␤ (1-43) in the presence or absence of 10 pM͞10 nM HNG and͞or 10 nM (0.35 g͞ml) rhIGBBP3 for 72 h. The WST-8 cell viability assay was performed by using Cell Counting Kit-8, as described (14) . The calcein assay was performed with calcein AM (Dojindo, Kumamoto, Japan), as described (14) .
Statistical Analyses. Experiments are means of triplicates, and each experiment was performed three to four times. Data are expressed as mean Ϯ SEM. Statistical analyses were performed with SPSS (SPSS, Chicago) by using an unpaired nonparametric Mann-Whitney test. Differences were considered statistically significant when P Ͻ 0.05.
Results
Cloning of HN as an IGFBP-3 Partner. A yeast two-hybrid system was used to identify IGFBP-3 partners. As a result, we isolated a 1,061-bp cDNA, in which a 723-bp fragment corresponded to positions 514-1235 of the HN cDNA (GenBank accession no. AY029066.1). The ORF for HN codes a 24-aa peptide, MAPRGFSCLLLLTSEIDLPVKRRA (14) . Yeast mating experiments confirmed the interaction between IGFBP-3 and HN, and cotransfected colonies disclosed potent ␤-galactosidase activity, which was completely absent in single transformants or cotransformants of either hybrid with empty vector. The HN clone was one of five positive clones that reproducibly bound IGFBP-3 in the yeast two-hybrid screen. It was cloned out in four separate experiments (see Supporting Text for details).
Confirmation of IGFBP-3 and HN Interaction.
To further verify the interaction between HN and IGFBP-3, we used dot blot and pull-down experiments (Fig. 1 ). HN peptide (0.3, 3.0, or 7.5 nmol), immobilized to poly(vinylidene difluoride) (PVDF) membrane, showed high affinity and specificity in binding to 125 I-labeled rhIGFBP-3 ( Fig. 1 A) . IGF-I (0.15, 1.5, and 3 nmol) and insulin (0.3, 3.0, and 7.5 nmol) were positive and negative controls, respectively. Two additional mutant HN peptides were also tested: HNG (HN-S14G) and HNA (HN-C8A) (both at 3.0 and 7.5 nmol) showed equal binding to IGFBP-3 when compared with native HN peptide (3.0 and 7.5 nmol) (Fig. 1B) . The dot blot experiments confirmed our original finding from the yeast two-hybrid screening, demonstrating association of HN and IGFBP-3, and further revealed that, although S14G and C8A mutations in the HN peptide are known to affect the rescue ability against AD-related insults (14) , the binding of these mutants to IGFBP-3 is not affected. As an additional independent confirmation, we used Ni-NTA agarose pull-down of IGFBP-3 with C terminally (His) 6x -tagged HN-peptide (Fig.  1C) . In this experiment, (His) 6x -tagged HN-peptide (1 nmol) pulled down rhIGFBP-3 (1 nmol) in a displaceable manner (Fig.  1C ). Untagged HN (100ϫ molar excess) displaced (His) 6x -tagged HN from IGFBP-3.
To further verify HN-IGFBP-3 interaction, we treated A172 glioblastoma cells with exogenous HN (10 M) overnight and immunoprecipitated whole-cell lysates with anti-human IGFBP-3 and normal IgG. IGFBP-3 is abundantly expressed in these cells as examined by Western blotting (data not shown) and as also reported earlier (16) . The precipitates from A172 cells were subjected to immunoblot analysis with anti-HN antibody. As shown in Fig. 1D , the Ϸ3-kDa HN coimmunoprecipitates with IGFBP-3 but not with the control IgG.
HN has been shown to be expressed in the testes of mice (15, 17) , and to confirm IGFBP-3-HN interaction in vivo, we immunoprecipitated mouse testis lysates with mouse-specific anti-IGFBP-3 antibody and control IgG. As shown in Fig. 1D , a band corresponding to the reported size of 4.5 kDa of rodent HN (18) was detected in ␣-IGFBP-3-precipitated samples but not in IgG-precipitated samples. Synthetic HN peptide was used as positive control (Ϸ3 kDa). The testis lysates were confirmed to express HN and IGFBP-3 by Western blot analysis (data not shown).
Structural IGFBP-3-Binding Properties of HN. Amino acids Pro-3, Ser-7, Cys-8, Leu-12, Thr-13, Ser-14, and Pro-19 were found to be essential for the rescue function of HN (14, 19) . However, the preliminary analysis of HNG and HNA in our dot blot experiment (Fig. 1B) suggested that the essential amino acids of HN with respect to IGFBP-3 binding might differ from those found to be important with respect to AD insults. To further analyze the nature of HN-binding properties, we performed an alanine scanning of the FLAG-tagged HN peptide ( Fig. 2 and Fig. 6 , which is published as supporting information on the PNAS web site). Two mutant HN peptides, Phe-6 to alanine (F6A-HN) and Lys-21 to alanine (K21A-HN), did not pull down rhIGFBP-3 in a M2 agarose column (Fig. 2 Left; Fig. 6 Upper), whereas all other HN mutants, as well as the native FLAG-tagged HN, did (see Fig. 6 ). However, when IGFBP-3 concentration was increased from 1 to 10 nmol (Fig. 2 Left, compare lanes 3-6 with 8-11), K21A-HN pulled down IGFBP-3, whereas F6A-HN still did not, suggesting that F6A-HN has a substantially lower affinity to IGFBP-3 than K21A-HN. A dot blot confirmation (Fig. 2 Right) showed that, whereas HN and K21A-HN (2.5 and 5.0 nmol) showed significant binding to To further analyze the binding affinity of HN and F6A to IGFBP-3, we performed a competitive cross-linking analysis with 125 I-HN (Fig. 6 Lower).
125
I-HN runs at Ϸ3 kDa (not shown), but when it is cross-linked, it forms dimers͞oligomers as also suggested recently by Terashita et al. (20) . We also performed a ligand dot blot experiment that confirmed the selfbinding ability of HN to 125 I-HN (data not shown). As expected, when IGFBP-3 (1 g) was cross-linked to 125 I-HN, the band shifted to the expected size of a HN-IGFBP-3 complex at Ϸ35-36 kDa. We competed 125 I-HN with HN that was added at decreasing concentrations (2, 1, and 0.1 g). HN was able to displace 125 I-HN completely at 2 and 1 g (i.e., Ϸ25ϫ and 10ϫ molar excess), whereas F6A-HN significantly competed only at 2 g (i.e., 25ϫ molar excess). The band intensities were analyzed with STORM PhosphorImager and IMAGEQUANT software (Molecular Dynamics). F6A-HN shows an order of magnitude reduced displacement ability when compared with HN (Fig. 6 Lower). (Fig. 3) . The N-terminal peptide blocked IGFBP-3 binding to IGF-I (data not shown), but it did not block 125 I-IGFBP-3 binding to HN or HNG. In contrast, the HBDdomain peptide did block HN͞HNG binding to a similar extent as full-length IGFBP-3 (Fig. 3) . This strongly suggests that the primary binding site of HN to the IGFBP-3 protein is within 18 aa of the C-terminal HBD domain. The N terminus of IGFBP-3 is considered the primary IGF-I-binding site, although the distal C terminus of IGFBP-3 is thought to also contribute to IGF-I binding. In separate experiments, we showed that the N-terminal peptide of IGFBP-3 strongly interferes with 125 I-IGFBP-3-IGF-I binding. In contrast, the HBD peptide had no effect on (Fig. 7 , which is published as supporting information on the PNAS web site). Labeled IGF-I could be found at Ϸ8 kDa and, when cross-linked to 1 g of IGFBP-3, it mobility-shifted to Ϸ38 kDa, corresponding to the size of a rhIGFBP-3-rhIGF-I complex (Fig. 7) . Addition of cold IGF-I (1.5 g) completely I-IGF-I was observed when HN or HNG (1 or 5 g, i.e., 10ϫ or 50ϫ molar excess to IGFBP-3) was present (Fig. 7) . However, the formation of an IGFBP-3-GF-I complex was still substantial. These results indicate that IGF and HN binding occur at different domains of the IGFBP-3 molecule (N-terminal for IGF-I and HBD for HN). Also of note is that no ternary complex of IGF-I, IGFBP-3, and HN was detected.
IGFBP-3 Induces Apoptosis in Neuronal and
Glial Cells. IGFBP-3 is known to induce apoptosis and cell growth inhibition in several cell types. In this study, we used a caspase-3͞-7-specific fluorometric assay (ApoONE, Promega) to measure the degree of apoptosis induction by IGFBP-3. Overall, the increase in caspase-3͞-7 activity varies between 50% and 80% in A172 and SH-SY5Y cells. In A172 glioblastoma cells, the IGFBP-3-induced caspase activation reaches its maximum at 1-6 h, after which it decreases (Fig. 4A) . In contrast, SH-SY5Y neuroblastoma cells have a slower response to IGFBP-3 addition, reaching the maximum at 8-12 h and decreasing slowly thereafter (Fig.  4A) . Furthermore, IGFBP-3-induced caspase activation in SH-SY5Y is blocked with simultaneous addition of IGF-I (100 ng͞ml) or phorbol 12-tetradecanoate 13-acetate (TPA) (50 ng͞ml) (Fig. 4C) . The addition of TPA also blocked ''basal'' caspase activation, decreasing it below serum-free control level (Fig. 4C) . As expected, the addition of IGF-I in serum free conditions also decreases the basal caspase activation (see below and Fig. 4C ).
HN Specifically Blocks IGFBP-3-Induced Cell Death.
To test whether the association of HN to IGFBP-3 has functional effects, we measured IGFBP-3-induced apoptosis in the presence of HN peptide and its derivatives. Our results show that, in addition to specifically binding to IGFBP-3, HN can potently inhibit IGFBP-3-induced apoptosis in vitro. We performed a series of experi- ments inducing apoptosis by exogenously added IGFBP-3 (1-4 g͞ml) in A172 glioblastoma and SH-SY5Y neuroblastoma cells. As described above, the A172 cells respond to IGFBP-3 more rapidly than SH-SY5Y cells (see above and Fig. 4A ), indicating differences in the mechanisms of IGFBP-3 actions between these cell lines. Further experiments revealed that the quick response of A172 glioblastoma cells was HN dependent, because it was potently inhibited by low (100 nM) concentrations of HN peptide or its derivatives, HNG and HNA (Fig. 4B) . However, the slow response of SH-SY5Y cells was HN independent, and caspase activity was not affected by addition of HN, HNG, or HNA (100 nM) (Fig. 4C) , whereas IGF-I (100 ng͞ml) and TPA (25 ng͞ml) still had a protective effect against IGFBP-3-induced apoptosis. That SH-SY5Y responded differentially to IGFBP-3, and HN did not affect this response, indicates that the effects of IGFBP-3 differ between cell lines, and that the actions of proapoptotic IGFBP-3 and antiapoptotic HN are interconnected.
To test whether the physical association between HN and IG-FBP-3 mediates any of these functional effects, we performed TUNEL staining of A172 cells that were treated with HN (500 nM) and IGFBP-3 (4 g͞ml) for 6 h in serum-free conditions. As expected, addition of IGFBP-3 to cells in serum-free media increased cell death, shown as increased TUNEL staining when compared with cells in serum-free media alone (Fig. 4D) . There was no significant increase in staining by serum-free medium alone when compared with samples maintained in 10% serum media. Also no significant differences were observed in cells treated with HN or F6A-HN alone. However, the presence of HN markedly prevented IGFBP-3-induced cell death, with HN-treated cells having similar staining to serum-free control cells. In contrast, addition of F6A-HN, the non-IGFBP-3-binding mutant of HN, was not able to block IGFBP-3-induced cell death in A172 cells, indicating that the IGFBP-3-binding property of HN is an important part of its cell survival protective actions. HN and IGFBP-3 . HN, and its more potent derivative, HNG, have been previously shown to specifically protect neuronal cells from A␤-induced toxicity (14) . However, the effects of exogenous IGFBP-3 on primary neuronal cells have not been examined.
Cooperative Interaction Between
First, by using WST-8 and calcein assays, we studied the effects of IGFBP-3 on primary neurons at doses from 1 to 100 nM. Addition of IGFBP-3 at 1-10 nM did not have any significant effects on neuronal viability examined up to 72 h (data not shown). However, addition of 100 nM IGFBP-3 had a modest (20%) decrease in neuronal viability at 72 h, when quantified with WST-8 and calcein assays (data not shown). Addition of HN, HNG, or HNA did not rescue the neurons from IGFBP-3, similar to results obtained in SH-SY5Y cells (see above and Fig. 4C) .
Second, to examine the effect of coaddition of IGFBP-3 and HN to A␤-induced toxicity, we treated primary cortical neurons with A␤ 1-43 (25 M) and HNG either with or without IGFBP-3 (10 nM) (Fig. 5) . HNG was used at increasing concentrations ranging from 10 pM to 10 nM. As expected, HNG significantly protected neurons from A␤ -induced death at a concentration of 1 nM and completely suppressed cell death at doses higher than 10 nM. No protection was observed with HNG at doses of 10-100 pM. Surprisingly, coaddition of IGFBP-3 dramatically potentiated HN action: whereas HNG alone at 100 pM had no effect on A␤ toxicity, in the presence of IGFBP-3, a dramatic increase in viability was observed. Ten nanomolar IGFBP-3 together with HNG exerted substantial protection at HNG concentrations of 100 pM (where none was seen without IGFBP-3), and full protection was seen at 1 nM, whereas 10 nM HNG was required without coaddition of IGFBP-3. Representative photomicrographs with calcein-specific fluorescence are shown in Fig. 6 (Fig. 5 Upper) . Viability was also quantified by measuring calcein-specific fluorescence in a 96-well format by using a spectrofluorometer. The addition of 10 nM IGFBP-3 potentiated HNG rescue at 100 pM by 10-fold, with viability increasing from 6% to 70%, as measured with calcein staining (P Ͻ 0.0001) (Fig. 5 Lower) . Discussion HN is a recently described small molecular-weight cell survivalpromoting agent that has been shown to potently function against AD-related insults in vitro. HN has been suggested to also have a broader survival-promoting activity: it protects human cerebrovascular smooth muscle cells from A␤-induced toxicity (22) . In addition, the activity of HN, or HN-like peptides, may involve protection against other types of cell stress as well, suggested by protection against serum withdrawal (23) , and N-methyl-D-aspartate-induced excitotoxic cell death in primary cortical͞glial cocultures by the recently cloned rat homologue of HN, rattin (18) . The origin of HN and how it is expressed in vivo are still largely unknown (14, 15) . HN peptide has a distinct expression pattern during mouse development and in humans is specifically expressed in the AD brain. It is found in large intact neurons of the occipital lobe and in reactive glial cells in the hippocampus (17) . Intracellular expression of HN is regulated in part by tripartite motif protein, TRIM11, through a ubiquitin-mediated protein degradation pathway (24) . The in vivo functions of HN and the implication of its expression in AD remain to be clarified.
Our findings indicate an interaction between the proapoptotic IGFBP-3 and HN. Moreover, we show that HN can specifically block IGFBP-3-induced cell death in glioblastoma cells. This protection depends on the IGFBP-3-binding capability of HN, as shown by the lack of protection by F6A-HN, a nonbinding mutant of IGFBP-3.
HN, when expressed in mammalian cells, needs to be secreted to be protective (14) . The L9R-HN mutant blocks the secretion of the peptide into the culture medium and also makes the peptide ineffective against cell death when transfected to cells. However, when administered exogenously, L9R-HN protects against cell death (14) , suggesting an extracellular action for HN and demonstrating its potential functional regulation by IGFBP-3. Indeed, reminiscent of its carrier function for the IGFs, IGFBP-3 could act as a carrier protein for HN both in the circulation and in tissues and thus could be an important regulator of extracellular HN levels as well as transport of HN to the CNS.
Our results demonstrate an association between the IGF system and AD involving IGFBP-3 and HN. HN binds to IGFBP-3 with high affinity and specificity in vitro, with Phe-6 being essential for the binding and also the antiapoptotic function in IGFBP-3-treated cells. Substitution of a critical cysteine residue at position 8 with alanine (HNA) completely destroys the protective activity of HN in AD-related in vitro systems (14, 25) . Notably, the residues important for IGFBP-3 binding are different, suggesting that HN acts in both IGFBP-3-dependent and independent fashion. Importantly, Phe-6 is conserved in the recently cloned rat homologue of HN, rattin, indicating the importance of IGFBP-3 binding (18). Guo et al. (15) predicted similar HN homologs by BLAST search in plants and nematodes as well, with Phe-6 being conserved (15) .
Recently, HN was shown to interfere with Bax activation and thereby protect from apoptosis (15) . HN prevents the mitochondrial translocation of Bax and subsequent release of cytochrome c. Reduced HN levels were shown to predispose cells to apoptotic stimuli in a Bax-dependent manner (15) . However, it cannot be ruled out that IGFBP-3 can act as a regulator of HN-Bax interaction. Because IGFBP-3 is present in extracellular, cytoplasmic, and nuclear compartments, this regulation can exist at multiple levels (6) . Thus, the exact mechanisms and consequences of IGFBP-3-HN-Bax interactions remain to be clarified.
The interaction between IGFBP-3 and HN appears to involve the HBD of IGFBP-3. Furthermore, we observed in crosslinking and ligand blot studies that HN did not bind IGF-I (data not shown). Consequently, HN may not act as a displacing molecule, liberating IGF-I from IGFBP-3. Because a growing body of evidence indicates changes in the expression of IGFs and IGFBPs in the CNS in response to injury, it is plausible that even though the IGFs are expressed at higher levels, the adjoining expression of the IGFBPs may abate their protective effects (11) . Because IGFBP-3 appears to be elevated in AD brain (12) , part of HN activity may be to block the apoptotic activity of IGFBP-3 in the CNS, having both direct and indirect survival effects.
Increased IGFBP-3 immunoreactivity in AD brain has been detected both in senile plaques and neurofibrillary tangles, strongly suggesting a role for IGFBP-3 in AD-related cell death (12) . If IGFBP-3 contributes to neuronal death during AD, our finding that HN inhibits IGFBP-3-induced caspase activation is of major significance. IGFBP-3 proapoptotic effects are transduced via at least two different cell death pathways. In SH-SY5Y neuroblastoma cells, the slow increase in caspase activity points to transcriptiondependent mechanisms that have been proposed to be mediated by RXR binding (6) . On the other hand, the rapid increase in caspase activation in A172 glioblastoma cells could be transcriptionindependent, involving possibly a putative IGFBP-3 receptor, which has been suggested to lead to inhibition of growth as observed in human breast cancer cells (26) .
An interesting twist is brought about by our results in primary neuronal cells, where the well established protection of HN against A␤-induced cell toxicity (14, 18, 20, 24) is potentiated by IGFBP-3. It is recognized in other systems that IGFBP-3 can also be proliferative and synergistic with IGF-I (27). Our results clearly enhance the recently emerging multimechanistic role of IGFBP-3 in the regulation of cell proliferation, survival, and apoptosis and also reveal that the interaction between IGFBP-3 and HN is of biological significance.
In summary, we cloned HN, an AD-related survival factor, as an interacting protein of IGFBP-3. HN is a recently described potent survival-promoting molecule, originally found to be expressed in the occipital lobe of Alzheimer brains. Our results not only show a physical association between IGFBP-3 and HN but also point to a functional interaction with cell type-specific effects, including opposing effects in some models and cooperative effects in others. That HN is expressed in surviving and unaffected areas of AD brain suggests it may be involved in antagonism of IGFBP-3 activity and cell death. In combination with recent studies in other cell culture models, HN represents a promising small-molecular-weight neuroprotective factor with therapeutic potential in AD. Our results validate further investigation of IGFBP-3-HN interaction in the CNS and reinforce the importance of the IGF system in relation to neuronal death and AD.
